Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $2.96 · Revenue $958.47M · 9 analysts
Est. EPS $11.32 · Revenue $3.90B · 10 analysts
Est. EPS $2.82 · Revenue $975.97M · 3 analysts
Est. EPS $3.21 · Revenue $1.01B · 6 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $4.0B | -0.9% | +0.8% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-144.3M | -1501.7% | +90.0% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +30.5% | -7.2% | +29.0% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | +12.6% | +125.3% | -0.8% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -3.6% | -1513.8% | +90.1% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $518.5M | +3.4% | +1102.1% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | +12.9% | +4.3% | +1093.9% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 96.9% | +23.1% | +2.6% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 1.29x | -8.5% | -1.0% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $7.1B | -5.2% | -2.6% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -2.91 vs 10.24 | -128.4% | -0.03 vs 2.96 | -101.0% |
| Revenue Surprise | $4.0B vs $4.0B | +0.3% | $1.0B vs $958.5M | +4.8% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 25, 2026 | FOSTER JAMES C | director | Common Stock | A | 12,429 | $208.44 |
| Aug 25, 2026 | FOSTER JAMES C | director | Common Stock | A | 21,132 | $194.12 |
| Aug 25, 2026 | FOSTER JAMES C | director | Common Stock | D | 33,561 | $300.00 |
| Aug 25, 2026 | FOSTER JAMES C | director | Stock Options (Right to Buy) | D | 12,429 | $208.44 |
| Aug 25, 2026 | FOSTER JAMES C | director | Stock Options (Right to Buy) | D | 21,132 | $194.12 |
Operator: Ladies and gentlemen, thank you for standing by, and welcome to the Charles River Laboratories Second Quarter 2026 Earnings Conference Call. This call is being recorded. [Operator Instructions] I would now like to turn the conference over to our host, Todd Spencer, Vice President of Investor Relations. Please go ahead. Todd Spencer: Good morning, and welcome to Charles River Laboratories Second Quarter 2026 Earnings Conference Call and Webcast. This morning, I am pleased to be joined by Birgit Girshick, our Chief Executive Officer; and by Glenn Coleman, our Executive Vice President and Chief Financial Officer. They will comment on our results for the second quarter of 2026 as well as our financial guidance. Following the presentation, they will respond to questions. There is a slide presentation associated with today's remarks, which will be posted on the Investor Relations section of our website at ir.criver.com. A webcast replay of this call will be available beginning approximately 2 hours after the call today and can be accessed on our Investor Relations website. The replay will be available through next quarter's conference call. I'd like to remind you of our safe harbor. All remarks that we make about future expectations, plans and prospects for the company constitute forward-looking statements under the Private Securities Litigation Act of 1995. Actual results may differ materially from those indicated. During this call, we will primarily discuss non-GAAP financial measures, which we believe help investors gain a meaningful understanding of our core operating results and guidance. The non-GAAP financial measures are not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP. In accordance with Regulation G, you can find the comparable GAAP measures and the reconciliation on the Investor Relations section of our website. I will now turn the call over to Birgit Girshick. Birgit Girshick: Thank you, Todd, and good morning. Today, I would like to discuss the progress that we made during the second quarter, both financially and on our refreshed strategic framework pathway to purpose. I'm pleased to report that we delivered on our second quarter financial targets, exceeding our prior outlook for the quarter and that we are raising our financial guidance for the year. We continue to remain focused on execution on achieving our financial targets and driving increased shareholder value as well as executing on our pathway to purpose strategy which includes working to modernize our company and the industry, strengthening our world-class scientific portfolio and offering a customized client-centric approach to drive growth. Execution of our pathway to purpose strategic initiatives and our financial goals will be the key to our future success. Let me now provide you with the recent highlights that demonstrate our progress on our pathway to purpose initiatives as well as our second …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Birgit Girshick | CEO & Director | USD 1,774,768 | Female | 1970 | Active |
Joseph W. LaPlume | Corporate Executive Vice President of Corporate Development & Strategy | USD 1,252,886 | Male | 1974 | Active |
Victoria L. Creamer | Corporate Executive Vice President & Chief People Officer | USD 1,225,929 | Female | 1970 | Active |
Glenn G. Coleman | Corporate Executive Vice President & Chief Financial Officer | USD 930,201 | Male | 1968 | Active |
Michael Gunnar Knell | Corporate Senior Vice President & Chief Accounting Officer | USD 912,225 | Male | 1977 | Active |
Mark Mintz | Corporate EVP, Chief Information Officer & Global Shared Services | — | Male | 1974 | Active |
Todd Spencer | Corporate Vice President of Investor Relations | — | Male | — | Active |
Amy Cianciaruso | Corporate Senior Vice President, Chief Communications Officer & Government Relations | — | Female | — | Active |
Kerry Dailey | Corporate Senior VP & Chief Legal Officer | — | Female | — | Active |
Brian F. Bathgate | Corporate Senior Vice President of European Safety Assessment | — | — | 1960 | Active |
Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits on several high-profile names while upgrading others to buy. Find out which stocks got the most surprising treatment before the opening bell.
Charles River Laboratories International NYSE: CRL reported second-quarter results that exceeded its prior outlook, citing improved demand in its Discovery and Safety Assessment, or DSA, business and stronger-than-expected manufacturing performance. The company raised its full-year revenue, earnings and free-cash-flow guidance while maintaining a cautious view that the recovery in biopharmaceutical demand will progress gradually.
Charles River Laboratories International, Inc. (CRL) Q2 2026 Earnings Call Transcript
Charles River beats Q2 earnings and revenue estimates, raises 2026 outlook and gains 7.9% in pre-market trading.
Here is how Charles River Laboratories (CRL) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.
